Paragon 28 Debt to Equity Ratio 2020-2022 | FNA

Current and historical debt to equity ratio values for Paragon 28 (FNA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Paragon 28 debt/equity for the three months ending June 30, 2022 was 0.24.
Paragon 28 Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-06-30 $0.09B $0.18B 0.50
2022-03-31 $0.08B $0.19B 0.46
2021-12-31 $0.04B $0.19B 0.22
2021-09-30 $0.10B $0.02B 3.98
2021-06-30 $0.00B $0.00B 0.00
2021-03-31 $0.00B $0.00B 0.00
2020-12-31 $0.00B 0.00
2020-09-30 $0.00B $0.00B 0.00
2019-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.384B $0.147B
Paragon 28 Inc. is a medical device company exclusively focused on the foot and ankle orthopedic market. Paragon 28 Inc. is based in ENGLEWOOD, Colo.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.023B 21.80
Edwards Lifesciences (EW) United States $54.208B 38.35
Alcon (ALC) Switzerland $30.150B 25.53
STERIS (STE) Ireland $17.307B 21.50
Teleflex (TFX) United States $9.641B 15.36
Fresenius Medical Care AG KGaA (FMS) Germany $8.287B 7.64
Penumbra (PEN) United States $7.435B 891.96
Globus Medical (GMED) United States $6.225B 31.75
Glaukos (GKOS) United States $2.693B 0.00
Integer Holdings (ITGR) United States $2.196B 17.17
Nevro (NVRO) United States $1.739B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.081B 16.55
Artivion (AORT) United States $0.519B 49.50